Generic Name and Formulations:
Cosyntropin 0.25mg/mL; pwd for IV or IM inj after reconstitution; preservative-free.
Amphastar Pharmaceuticals, Inc.
Indications for CORTROSYN:
For use in the screening of patients presumed to have adrenocortical insufficiency.
Adults and Children:
Give by IV, IM inj or IV infusion over 4–8hrs. <2yrs: 0.125mg. ≥2yrs: Usual range: 0.25–0.75mg.
Patients with raised bilirubin or where plasma contains free hemoglobin: falsely high fluorescence measurements may result. Pregnancy (Cat.C). Nursing mothers.
May accentuate the electrolyte loss associated with diuretics. May exhibit abnormally high plasma cortisol levels if patients taking cortisone, hydrocortisone, spironolactone, estrogens.
Hypersensitivity reactions (eg, rare, but possible), bradycardia, tachycardia, hypertension, peripheral edema, rash.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Triiodothyronine in the Treatment of Bipolar Depression
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed
- Intranasal Oxytocin Reduces Negative Effects, Improves Cognitive Function in Schizophrenia
- E-Cigarettes Associated With More Harms Than Benefits at Population Level
- Examining Rates of Long-Term Opioid Use in Youth With Psychiatric Disorders
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Researchers Identify Novel Potential Biomarkers for Autism
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Personal Health Information Found in Recycling
- Nightmares in Military Personnel Frequently Comorbid With Mental Health Disorders
- Potential for SERMs as Adjunctive Therapy for Schizophrenia
- Addressing Racial Disparities in Bipolar Disorder Treatment
- Negative Symptoms Increase Cardiovascular Risk in Schizophrenia